Phase II Safety Study of 2 Dose Regimens of HepaStem in Patients With ACLF

Main Inclusion Criteria: * Diagnosed cirrhosis * Patient with Acute Decompensation of cirrhosis * Serum total Bilirubin ≥ 6 mg/dL (≥100 umol/L) * The INR measurement has to be : 1.2 ≤ INR \< 2 Main Exclusion Criteria: * Absence of portal vein flow * Known or medical history of thrombotic events * Gastrointestinal hemorrhage requiring blood transfusion * Variceal bading or sclerosis within 4 weeks before infusion * Septic shock or non-controlled bacterial infection * Clinical evidence of aspergilus infection. * Circulatory failure * Respiratory disordered * Coagulation disorders defined as INR ≥ 2, Fibrinogen \< 100 mg/dL or Platelets \< 50.000/mm3 * MELD score \> 30. * Major invasive procedure within 4 weeks before infusion * Previous organ transplantation and/or ongoing immunosuppressive treatments. * Renal failure due to chronic kidney disease. * Clinically significant left-right cardiac shunt.